MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

Search

Ionis Pharmaceuticals Inc

Open

SectorGezondheidszorg

29.64 1.37

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.69

Max

29.84

Belangrijke statistieken

By Trading Economics

Inkomsten

36M

-104M

Verkoop

93M

227M

K/W

Sectorgemiddelde

539.57

57.333

EPS

-0.43

Winstmarge

-46.055

Werknemers

1,069

EBITDA

44M

-81M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+87.59% upside

Dividenden

By Dow Jones

Volgende Winsten

30 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-162M

4.5B

Vorige openingsprijs

28.27

Vorige sluitingsprijs

29.64

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Ionis Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 sep 2024, 17:01 UTC

Top Nieuws

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 sep 2024, 11:00 UTC

Top Nieuws

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Peer Vergelijking

Prijswijziging

Ionis Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

87.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55.47 USD  87.59%

Hoogste 78 USD

Laagste 38 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ionis Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

20 ratings

12

Buy

8

Hold

0

Sell

Technische score

By Trading Central

29.04 / 30.12Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.